China Anti-Rheumatic Drug Market Size, Share, Opportunities, COVID-19 Impact, And Trends By Type Of Disease (Osteoarthritis, Rheumatoid Arthritis, Gout, Lupus, Others), By Type Of Molecule (Pharmaceuticals, Biopharmaceuticals) And By Sales Channel (Prescription, Over-the-counter (OTC)) - Forecasts From 2020 To 2025
Published:  Jun 2020 Report Code: KSI061613655 Pages: 75

China antirheumatic drugs market was valued at US$17,516.041 million in 2019. A growing number of patients suffering from arthritis in China is the major driver of the antirheumatic drugs market in the country.  According to the data from the Osteoarthritis Research Society International, its 2018 report showed that more than 8 percent of the total Chinese population is living with physician-diagnosed symptomatic knee OA while the prevalence of any type of arthritis/rheumatism was around 32.3 percent. As such, changing lifestyles will continue this trend during the next five years, thus positively impacting the market growth of antirheumatic drugs in China. High investments in R&D to develop generic drugs is also a driving factor for the market growth of antirheumatic drugs in China. The country is the leading exporter of generic drugs across the globe. With burgeoning middle-class and rapidly-aging society, China’s pharmaceutical industry will continue to grow during the next five years, thereby bolstering the antirheumatic drugs market growth. 

The recent COVID-19 global pandemic outbreak has also impacted the growth of the antirheumatic drug market in China. Pharmaceutical companies are testing existing drugs that can be effective in treating symptoms in patients infected with this novel coronavirus. In March 2020, China’s National Health Commission approved Roche’s Actemra to treat serious coronavirus patients with lung damage. The drug is usually for rheumatoid arthritis, first approved by the U.S. FDA in 2010. With a continuous rise in the number of COVID-19 patients, the demand for this drug is increasing, thus positively impacting the market growth.    

China Antirheumatic Drugs market has been segmented based on the type of disease, type of molecule, and sales channel. By type of disease, the market has been segmented as osteoarthritis,rheumatoid arthritis, gout, lupus, and others. By type of molecule, China Antirheumatic Drugs market has been classified into pharmaceuticals and biopharmaceuticals. The market segmentation has also been done by sales channel as prescription and over-the-counter (OTC).

Segmentation

  • By Type of Disease
    • Osteoarthritis
    • Rheumatoid Arthritis
    • Gout
    • Lupus
    • Others
  • By Type of Molecule
    • Pharmaceuticals
    • Biopharmaceuticals
  • By Sales Channel
    • Prescription
    • Over-The-Counter (OTC)
1. Introduction
1.1. Market Definition
1.2. Market Segmentation
 
2. Research Methodology
2.1. Research Data
2.2. Assumptions
 
3. Executive Summary
3.1. Research Highlights
 
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
 
5. China Antirheumatic Drugs Market Analysis, By Type of Disease
5.1. Introduction
5.2. Osteoarthritis
5.3. Rheumatoid Arthritis
5.4. Gout
5.5. Lupus
5.6. Others
 
6. China Antirheumatic Drugs Market Analysis, By Type of Molecule
6.1. Introduction
6.2. Pharmaceuticals
6.3. Biopharmaceuticals
 
7. China Antirheumatic Drugs Market Analysis, By Sales Channel
7.1. Introduction
7.2. Prescription
7.3. Over-The-Counter (OTC)
 
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
 
9. Company Profiles
9.1. Pfizer Inc.
9.2. F. Hoffmann-La Roche Ltd
9.3. UCB S.A.
9.4. Eli Lilly and Company
9.5. AbbVie Inc.

Pfizer Inc.

F. Hoffmann-La Roche Ltd

UCB S.A.

Eli Lilly and Company

AbbVie Inc.

Pricing

Explore Custom Options available with this study:

  •  Request customization
  •  Buy sections of the study
  •  Buy country specific report
  •  Request excel, Historical data
  •  Subscription inquiry
  •  Request special pricing

Our Value Proposition

Analyst Support

All our studies come with 2 months of analyst support.


Confidentiality

We are in compliance with the global privacy laws.

Connect With Us